Press Releases + New

Date	Title and Summary	View
Toggle SummaryFeb 03, 2009	PRO-PHARMACEUTICALS UPDATES RIGHTS OFFERING: FILES AMENDED REGISTRATION STATEMENT	View HTML PRO-PHARMACEUTICALS UPDATES RIGHTS OFFERING: FILES AMENDED REGISTRATION STATEMENT 16.6 KB
Toggle SummaryFeb 17, 2009	PRO-PHARMACEUTICALS POSTPONES RIGHTS OFFERING	View HTML PRO-PHARMACEUTICALS POSTPONES RIGHTS OFFERING 13.3 KB
Toggle SummaryFeb 17, 2009	PRO-PHARMACEUTICALS NAMES THEODORE D. ZUCCONI, PH.D., CHIEF EXECUTIVE OFFICER Gil Amelio, Ph.D., Jim Czirr, Rod Martin, J.D., Peter Traber, M.D., Named to the Company's Board of Directors	View HTML PRO-PHARMACEUTICALS NAMES THEODORE D. ZUCCONI, PH.D., CHIEF EXECUTIVE OFFICER 13.3 KB
Toggle SummaryFeb 17, 2009	PRO-PHARMACEUTICALS CLOSES INITIAL $1.8 MILLION TRANCHE OF UP TO $6.0 MILLION PRIVATE PLACEMENT	View HTML PRO-PHARMACEUTICALS CLOSES INITIAL $1.8 MILLION TRANCHE OF UP TO $6.0 MILLION PRIVATE PLACEMENT 13.3 KB
Toggle SummaryMar 29, 2009	PRO-PHARMACEUTICALS LICENSES TO PROCAPS S.A. EXCLUSIVE MARKETING and DISTRIBUTION RIGHTS to COMMERCIALIZE DAVANAT® to TREAT CANCER in COLOMBIA, SOUTH AMERICA	View HTML PRO-PHARMACEUTICALS LICENSES TO PROCAPS S.A. EXCLUSIVE MARKETING and DISTRIBUTION RIGHTS to COMMERCIALIZE DAVANAT® to TREAT CANCER in COLOMBIA, SOUTH AMERICA 20.7 KB
Toggle SummaryApr 15, 2009	Pro-Pharmaceuticals' DAVANAT® Prevents Mucositis, a Serious Side Effect of Chemotherapy, in All 100 Cancer Patients Treated	View HTML Pro-Pharmaceuticals' DAVANAT® Prevents Mucositis, a Serious Side Effect of Chemotherapy, in All 100 Cancer Patients Treated 17.7 KB
Toggle SummaryApr 29, 2009	PRO-PHARMACEUTICALS ENGAGES PERCEPTIVE IMAGINEERING TO MARKET DAVANAT® IN CENTRAL & SOUTH AMERICA	View HTML PRO-PHARMACEUTICALS ENGAGES PERCEPTIVE IMAGINEERING TO MARKET DAVANAT® IN CENTRAL & SOUTH AMERICA 17.1 KB
Toggle SummaryMay 15, 2009	Pro-Pharmaceuticals Reports First Quarter 2009 Financial Results	View HTML Pro-Pharmaceuticals Reports First Quarter 2009 Financial Results 19.6 KB
Toggle SummaryMay 30, 2009	PRO-PHARMACEUTICALS REPORTS FULL YEAR and FOURTH QUARTER 2008 FINANCIAL RESULTS	View HTML PRO-PHARMACEUTICALS REPORTS FULL YEAR and FOURTH QUARTER 2008 FINANCIAL RESULTS 18.4 KB
Toggle SummaryJun 24, 2009	PRO-PHARMACEUTICALS' CHIEF SCIENTIST PUBLISHED ARTICLES IN THREE PRESTIGIOUS PEER-REVIEWED JOURNALS NMR Studies Further Define DAVANAT®'s Mechanism of Action with Galectin Receptors Found on Solid Tumors	View HTML PRO-PHARMACEUTICALS' CHIEF SCIENTIST PUBLISHED ARTICLES IN THREE PRESTIGIOUS PEER-REVIEWED JOURNALS 17.2 KB
Toggle SummaryJul 06, 2009	PRO-PHARMACEUTICALS CLOSES $500,000 TRANCHE; BRINGS TOTAL TO $3.2 MILLION OF $6.0 MILLION PRIVATE PLACEMENT	View HTML PRO-PHARMACEUTICALS CLOSES $500,000 TRANCHE; BRINGS TOTAL TO $3.2 MILLION OF $6.0 MILLION PRIVATE PLACEMENT 17.7 KB
Toggle SummaryJul 14, 2009	PRO-PHARMACEUTICALS NAMES NOTED PHYSICIAN DR. GILBERT S. OMENN TO SCIENTIFIC ADVISORY BOARD Professor of Internal Medicine, Human Genetics and Public Health at the University of Michigan. Former CEO of the University of Michigan Health System.	View HTML PRO-PHARMACEUTICALS NAMES NOTED PHYSICIAN DR. GILBERT S. OMENN TO SCIENTIFIC ADVISORY BOARD 17 KB
Toggle SummaryJul 17, 2009	PRO-PHARMACEUTICALS PREVAILS IN TRADE SECRET LAWSUIT Court Dismisses Claims For Lack of Prosecution	View HTML PRO-PHARMACEUTICALS PREVAILS IN TRADE SECRET LAWSUIT 17.3 KB
Toggle SummaryJul 23, 2009	COURT ISSUES JUDGMENT DISMISSING TRADE SECRET LAWSUIT AGAINST PRO-PHARMACEUTICALS	View HTML COURT ISSUES JUDGMENT DISMISSING TRADE SECRET LAWSUIT AGAINST PRO-PHARMACEUTICALS 15.5 KB
Toggle SummaryAug 14, 2009	Pro-Pharmaceuticals Reports Second Quarter and First Six Months 2009 Financial Results	View HTML Pro-Pharmaceuticals Reports Second Quarter and First Six Months 2009 Financial Results 19.9 KB
Toggle SummaryAug 24, 2009	Pro-Pharmaceuticals Appoints Arthur R. "Bobby" Greenberg to its Board of Directors	View HTML Pro-Pharmaceuticals Appoints Arthur R. "Bobby" Greenberg to its Board of Directors 16 KB
Toggle SummaryAug 26, 2009	PRO-PHARMACEUTICALS TO PRESENT A CORPORATE UPDATE AT THE RODMAN & RENSHAW ANNUAL GLOBAL INVESTMENT CONFERENCE	View HTML PRO-PHARMACEUTICALS TO PRESENT A CORPORATE UPDATE AT THE RODMAN & RENSHAW ANNUAL GLOBAL INVESTMENT CONFERENCE 13.7 KB
Toggle SummarySep 24, 2009	PRO-PHARMACEUTICALS TO PRESENT A CORPORATE UPDATE AT THE MAXIM GROUP GROWTH CONFERENCE	View HTML PRO-PHARMACEUTICALS TO PRESENT A CORPORATE UPDATE AT THE MAXIM GROUP GROWTH CONFERENCE 13.7 KB
Toggle SummaryOct 06, 2009	PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE; BRINGS TOTAL TO $3.8 MILLION OF $6.0 MILLION PRIVATE PLACEMENT	View HTML PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE; BRINGS TOTAL TO $3.8 MILLION OF $6.0 MILLION PRIVATE PLACEMENT 15.2 KB
Toggle SummaryNov 04, 2009	PRO-PHARMACEUTICALS CLOSES $310,000 TRANCHE; BRINGS TOTAL TO $4.1 MILLION OF $6.0 MILLION PRIVATE PLACEMENT	View HTML PRO-PHARMACEUTICALS CLOSES $310,000 TRANCHE; BRINGS TOTAL TO $4.1 MILLION OF $6.0 MILLION PRIVATE PLACEMENT 16.2 KB
Toggle SummaryNov 13, 2009	Pro-Pharmaceuticals Reports Third Quarter Financial Results	View HTML Pro-Pharmaceuticals Reports Third Quarter Financial Results 17.1 KB
Toggle SummaryDec 10, 2009	PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE	View HTML PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE 16.2 KB
Toggle SummaryDec 15, 2009	THE LUDWIG INSTITUTE AND PRO-PHARMACEUTICALS COLLABORATE TO TEST DAVANAT®'s ABILITY TO ENHANCE THE FUNCTION OF ANTI-TUMOR T LYMPHOCYTES Pro-Pharmaceuticals' DAVANAT® Targets Galectin Receptors on Cancer Cells and Removes Their Ability to Evade the Immune System	View HTML THE LUDWIG INSTITUTE AND PRO-PHARMACEUTICALS COLLABORATE TO TEST DAVANAT®'s ABILITY TO ENHANCE THE FUNCTION OF ANTI-TUMOR T LYMPHOCYTES 20.4 KB
Toggle SummaryDec 17, 2009	PRO-PHARMACEUTICALS ANNOUNCES SIGNIFICANT ADVANCE IN DEFINING DAVANAT®'s MECHANISM OF ACTION BASED ON EXPERIMENTS DONE AT THE UNIVERSITY OF MINNESOTA AND THE LUDWIG INSTITUTE IN BRUSSELS, BELGIUM Studies Demonstrate DAVANAT® Binds To Galectin-1 and Galectin-3 Receptors That Control Angiogenesis and the Tumor's Ability To Evade the Immune System	View HTML PRO-PHARMACEUTICALS ANNOUNCES SIGNIFICANT ADVANCE IN DEFINING DAVANAT®'s MECHANISM OF ACTION BASED ON EXPERIMENTS DONE AT THE UNIVERSITY OF MINNESOTA AND THE LUDWIG INSTITUTE IN BRUSSELS, BELGIUM 22.2 KB
Toggle SummaryFeb 02, 2010	PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE	View HTML PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE 15.2 KB
Toggle SummaryFeb 10, 2010	PRO-PHARMACEUTICALS RECEIVES FINAL TRANCHE OF FUNDING FROM FEDERAL GRANT; RAISES CASH POSITION TO $8 MILLION	View HTML PRO-PHARMACEUTICALS RECEIVES FINAL TRANCHE OF FUNDING FROM FEDERAL GRANT; RAISES CASH POSITION TO $8 MILLION 17 KB
Toggle SummaryMar 11, 2010	PRO-PHARMACEUTICALS CLOSES $335,000 TRANCHE	View HTML PRO-PHARMACEUTICALS CLOSES $335,000 TRANCHE 15.4 KB
Toggle SummaryMar 12, 2010	PRO-PHARMACEUTICALS REPORTS FULL YEAR and FOURTH QUARTER 2009 FINANCIAL RESULTS	View HTML PRO-PHARMACEUTICALS REPORTS FULL YEAR and FOURTH QUARTER 2009 FINANCIAL RESULTS 18 KB
Toggle SummaryApr 28, 2010	COLOMBIAN PRESIDENT URIBE WELCOMES PRO-PHARMACEUTICALS AND INTRODUCTION OF DAVANAT® TO COLOMBIA	View HTML COLOMBIAN PRESIDENT URIBE WELCOMES PRO-PHARMACEUTICALS AND INTRODUCTION OF DAVANAT® TO COLOMBIA 20.5 KB
Toggle SummaryMay 04, 2010	PRO-PHARMACEUTICALS CLOSES $310,000 TRANCHE FROM 10X FUND	View HTML PRO-PHARMACEUTICALS CLOSES $310,000 TRANCHE FROM 10X FUND 16.2 KB
Toggle SummaryMay 11, 2010	PRO-PHARMACEUTICALS CLOSES FINAL $570,000 TRANCHE FROM 10X FUND TO COMPLETE $6 MILLION RAISE	View HTML PRO-PHARMACEUTICALS CLOSES FINAL $570,000 TRANCHE FROM 10X FUND TO COMPLETE $6 MILLION RAISE 17.1 KB
Toggle SummaryMay 12, 2010	PRO-PHARMACEUTICALS REPORTS FIRST QUARTER 2010 FINANCIAL RESULTS	View HTML PRO-PHARMACEUTICALS REPORTS FIRST QUARTER 2010 FINANCIAL RESULTS 16.2 KB
Toggle SummaryMay 24, 2010	PRO-PHARMACEUTICALS PREPARES PHASE III DAVANAT® TRIAL FOR SECOND HALF 2010 Peter G. Traber, M.D. Joins Trial Design Team to Finalize and Implement Strategy for FDA Approval	View HTML PRO-PHARMACEUTICALS PREPARES PHASE III DAVANAT® TRIAL FOR SECOND HALF 2010 16.4 KB
Toggle SummaryJun 15, 2010	FORMER GLAXO SMITH KLINE CHIEF MEDICAL OFFICER PETER G. TRABER, M.D., NAMED CHIEF MEDICAL OFFICER OF PRO-PHARMACEUTICALS Dr. Traber Will Lead Design of Phase lll Colorectal Cancer Trial for DAVANAT® and the Company's FDA Approval Strategy	View HTML FORMER GLAXO SMITH KLINE CHIEF MEDICAL OFFICER PETER G. TRABER, M.D., NAMED CHIEF MEDICAL OFFICER OF PRO-PHARMACEUTICALS 18.3 KB
Toggle SummaryJun 22, 2010	PRO-PHARMACEUTICALS RECEIVES FIRST COMMERCIAL ORDER FOR DAVANAT® PROCAPS S.A. To Make Upfront Payment and Will Be Responsible for the Approval, Distribution, Marketing and Sales of DAVANAT® in Colombia	View HTML PRO-PHARMACEUTICALS RECEIVES FIRST COMMERCIAL ORDER FOR DAVANAT® 19.3 KB
Toggle SummaryAug 13, 2010	PRO-PHARMACEUTICALS REPORTS SECOND QUARTER 2010 AND SIX MONTHS FINANCIAL RESULTS	View HTML PRO-PHARMACEUTICALS REPORTS SECOND QUARTER 2010 AND SIX MONTHS FINANCIAL RESULTS 18.1 KB
Toggle SummaryAug 24, 2010	PRO-PHARMACEUTICALS' EXECUTIVES TO PRESENT CORPORATE UPDATE AT THREE INVESTOR CONFERENCES IN SEPTEMBER Rodman and Renshaw Annual Global Investment Conference; BioPharm America 2010 MassBio Investors Forum, and Accredited Members Fall 2010 Small/Micro Cap Conference	View HTML PRO-PHARMACEUTICALS' EXECUTIVES TO PRESENT CORPORATE UPDATE AT THREE INVESTOR CONFERENCES IN SEPTEMBER 15.3 KB
Toggle SummarySep 10, 2010	PRO-PHARMACEUTICALS' PRESENTATION AT RODMAN AND RENSHAW'S ANNUAL GLOBAL INVESTMENT CONFERENCE TO BE WEBCAST LIVE	View HTML PRO-PHARMACEUTICALS' PRESENTATION AT RODMAN AND RENSHAW'S ANNUAL GLOBAL INVESTMENT CONFERENCE TO BE WEBCAST LIVE 16.5 KB
Toggle SummarySep 13, 2010	PRO-PHARMACEUTICALS COLLABORATES WITH NUMODA TO MANAGE PHASE lll CLINICAL TRIAL TO INCREASE SPEED-TO-MARKET FOR DAVANAT®	View HTML PRO-PHARMACEUTICALS COLLABORATES WITH NUMODA TO MANAGE PHASE lll CLINICAL TRIAL TO INCREASE SPEED-TO-MARKET FOR DAVANAT® 16.9 KB
Toggle SummaryOct 28, 2010	PRO-PHARMACEUTICALS SHIPS FIRST COMMERCIAL ORDER FOR DAVANAT® South American Distributor PROCAPS S.A. To Market and Sell DAVANAT® in Colombia, South America	View HTML PRO-PHARMACEUTICALS SHIPS FIRST COMMERCIAL ORDER FOR DAVANAT® 18.5 KB
Toggle SummaryNov 02, 2010	PRO-PHARMACEUTICALS TO RECEIVE $489,000 IN FEDERAL GRANTS FOR ITS GALECTIN-TARGETING CANCER AND LIVER FIBROSIS COMPOUNDS	View HTML PRO-PHARMACEUTICALS TO RECEIVE $489,000 IN FEDERAL GRANTS FOR ITS GALECTIN-TARGETING CANCER AND LIVER FIBROSIS COMPOUNDS 18.7 KB
Toggle SummaryNov 12, 2010	PRO-PHARMACEUTICALS REPORTS THIRD QUARTER 2010	View HTML PRO-PHARMACEUTICALS REPORTS THIRD QUARTER 2010 19.3 KB
Toggle SummaryDec 07, 2010	PRO-PHARMACEUTICALS EXPANDS PATENT COVERAGE TO AUSTRALIA Patent Covers Use of DAVANAT® with Chemotherapy to Increase Effectiveness and Reduce Side Effects of Cancer Treatments	View HTML PRO-PHARMACEUTICALS EXPANDS PATENT COVERAGE TO AUSTRALIA 17.4 KB
Toggle SummaryDec 21, 2010	PRO-PHARMACEUTICALS & MOUNT SINAI SCHOOL OF MEDICINE ANNOUNCE NEW LIVER FIBROSIS RESEARCH COLLABORATION	View HTML PRO-PHARMACEUTICALS & MOUNT SINAI SCHOOL OF MEDICINE ANNOUNCE NEW LIVER FIBROSIS RESEARCH COLLABORATION 22.5 KB
Toggle SummaryJan 04, 2011	PRO-PHARMACEUTICALS TO PRESENT CORPORATE UPDATE AT SAN FRANCISCO BIOTECH CONFERENCE	View HTML PRO-PHARMACEUTICALS TO PRESENT CORPORATE UPDATE AT SAN FRANCISCO BIOTECH CONFERENCE 16.5 KB
Toggle SummaryJan 06, 2011	PRO-PHARMACEUTICALS CLOSES $2.1 MILLION OFFERING Warrant Exercises Generate Additional $1 Million	View HTML PRO-PHARMACEUTICALS CLOSES $2.1 MILLION OFFERING 16.8 KB
Toggle SummaryJan 10, 2011	PRO-PHARMACEUTICALS RECEIVES POSITIVE FDA FEEDBACK ON DAVANAT® PHASE III CLINICAL TRIAL DESIGN TO TREAT PATIENTS WITH COLORECTAL CANCER	View HTML PRO-PHARMACEUTICALS RECEIVES POSITIVE FDA FEEDBACK ON DAVANAT® PHASE III CLINICAL TRIAL DESIGN TO TREAT PATIENTS WITH COLORECTAL CANCER 17.3 KB
Toggle SummaryFeb 08, 2011	PRO-PHARMACEUTICALS TO PRESENT CORPORATE UPDATE AT BIO CEO & INVESTOR CONFERENCE	View HTML PRO-PHARMACEUTICALS TO PRESENT CORPORATE UPDATE AT BIO CEO & INVESTOR CONFERENCE 18 KB
Toggle SummaryMar 09, 2011	PRO-PHARMACEUTICALS NAMES PETER G. TRABER, M.D., FORMER GLAXOSMITHKLINE CHIEF MEDICAL OFFICER & PRESIDENT EMERITUS OF BAYLOR COLLEGE OF MEDICINE, PRESIDENT & CHIEF EXECUTIVE OFFICER	View HTML PRO-PHARMACEUTICALS NAMES PETER G. TRABER, M.D., FORMER GLAXOSMITHKLINE CHIEF MEDICAL OFFICER & PRESIDENT EMERITUS OF BAYLOR COLLEGE OF MEDICINE, PRESIDENT & CHIEF EXECUTIVE OFFICER 19 KB
Toggle SummaryMar 15, 2011	PRO-PHARMACEUTICALS REPORTS FULL YEAR and FOURTH QUARTER 2010 FINANCIAL RESULTS	View HTML PRO-PHARMACEUTICALS REPORTS FULL YEAR and FOURTH QUARTER 2010 FINANCIAL RESULTS 26.1 KB